补脾胃泻阴火升阳汤联合美沙拉嗪治疗溃疡性结肠炎患者临床疗效观察

Clinical Efficacy of Bupiwei Xieyinghuo Shengyang Tang Combined with Mesalazine in Treatment of Ulcerative Colitis

目的:观察补脾胃泻阴火升阳汤联合美沙拉嗪治疗溃疡性结肠炎的临床疗效及对炎症细胞因子的影响。方法:选择符合纳入标准的溃疡性结肠炎患者195例,采用简单数字的随机方法分为对照1组,对照2组和治疗组,每组65例。对照1组给予美沙拉嗪肠溶片口服,1 g/次,3次/d(tid),对照2组患者在口服美沙拉嗪肠溶片的基础上给予陈李济补脾益肠丸口服,6 g/次,tid。治疗组患者在口服美沙拉嗪肠溶片的基础上给予补脾胃泻阴火升阳汤口服,每次100 mL,tid。观察3组患者治疗前后症状、大肠黏膜积分变化和细胞因子高敏C反应蛋白(high sensitivity C-reaction protein,hs-CRP),白细胞介素-6(interleukin-6,IL-6),肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)水平变化,统计临床疗效。结果:治疗组治疗后在证候积分(腹痛、腹泻、脓血便),大肠黏膜积分、细胞因子(hs-CRP,IL-6,TNF-α)水平较对照1组,对照2组均明显降低(P<0.05);治疗组,对照1组,对照2组临床疗效总有效率分别为93.85%,78.46%,81.54%,治疗组临床疗效优于对照1组,对照2组(P<0.05)。结论:补脾胃泻阴火升阳汤联合美沙拉嗪能够有效地缓解溃疡性结肠炎患者临床症状及大肠黏膜病变,改善细胞因子水平,值得进一步推广及应用。

Objective： To observe the clinical efficacy of Bupiwei Xieyinghuo Shengyang Tang combined with mesalazine in the treatment of ulcerative colitis, and their effect on inflammatory cytokines. Method： A total of 195 patients with ulcerative colitis were selected and divided with the random number table method into control group 1, control group 2 and treatment group, with 65 cases in each group. The control group 1 was orally given mesalazin enteric-coated table, 1 g/time, tid. In addition to oral administration with mesalazin enteric-coated table, the control group 2 was also orally given Chenliji Bupi Yichang pill, 6 g/time, tid. The treatment group was treated with Bupiwei Xieyinghuo Shengyang Tang, 100 mL/time, tid, in addition to oral administration with mesalazin enteric-coated table. Before and after treatment, symptoms, colorectal mucosa score changes, high sensitivity C-reaction protein （hs-CRP） , interleukin-6 （IL-6） and tumor necrosis factor-α （TNF-α） levels wereobserved, and statistics was made for the clinical efficacy. Result： The treatment group showed reductions in symptoms （abdominal pain, diarrhea, pus and blood stool）, colon mucosa score, cytokines （hs-CRP, IL-6, TNF- alpha） compared with control group 1 and control group 2 （P 〈 0.05）. The total effective rates of treatment group, control group 1 and control group 2 were 93.85% , 78.46% , 81.54% , respectively, indicating treatment group was superior to control group 1 and control group 2 in the clinical efficacy （ P 〈 0.05 ）. Conclusion ： Bupiwei Xieyinghuo Shengyang Tang combined with mesalazine can effectively alleviate clinical symptoms of ulcerative colitis and colorectal mucosa, improve the level of cytokines, and provide an effective prescription for clinical explorations for traditional Chinese medicine for the treatment of ulcerative colitis, and is worth further promotion and application.